Q-omics provides the consensus-scored RPS26P13 profile across patient tissues and cancer cell-line models. RPS26P13 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPS26P13 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, RPS26P13 RNA expression shows 9,308 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where RPS26P13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS26P13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS26P13 survival associations across molecular data types. RPS26P13 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS26P13 RNA expression–survival associations across cancer types. High RPS26P13 expression shows unfavorable associations in ACC, UCEC and PAAD, but favorable associations in CESC, LUSC and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPS26P13 RNA expression.
This table summarizes RPS26P13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPS26P13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS26P13 shows higher tumor expression in COAD, KIRC, LIHC and KIRP. The COAD box plot shows higher RPS26P13 RNA expression in tumor versus normal tissue (log2 FC = +0.821, t-test p < 0.001).
This table shows molecular features associated with RPS26P13 in patient tissues and cancer cell lines. In patient samples, RPS26P13 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
